<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Polidocanol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06811</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins &#8804;1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06811/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06811/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06811.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06811.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06811.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06811.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06811.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06811">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Dodecylpolyethyleneglycolether</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Hydroxyl polyethoxy dodecane</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Laureth 9</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lauromacrogol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Macrogol lauryl ether</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oxypolyethoxydodecane</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>PEG-9 lauryl alcohol </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>POE-9 lauryl alcohol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Polydocanol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Asclera</td><td>Chemische Fabrik Kreussler &amp; Co. GmbH.</td></tr><tr><td>VARITHENA</td><td>PROVENSIS</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/sclerosing-solutions">Sclerosing Solutions</a></li>
<li><a href="/mesh/detergents">Detergents</a></li></ul></td></tr><tr><th>CAS number</th><td>9002-92-0</td></tr><tr><th>Weight</th><td>Average: 230.3868<br>Monoisotopic: 230.224580204</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>30</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>SFNALCNOMXIBKG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H30O2/c1-2-3-4-5-6-7-8-9-10-11-13-16-14-12-15/h15H,2-14H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(dodecyloxy)ethan-1-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCCCCCCCCCOCCO</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB06811.gif?1367014379">show</a>(10.2 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organonitrogen Compounds</td></tr><tr><th>Class</th><td>Amines</td></tr><tr><th>Subclass</th><td>Polyamines</td></tr><tr><th>Direct parent</th><td>Polyamines</td></tr><tr><th>Alternative parents</th><td>Primary Alcohols; Ethers</td></tr><tr><th>Substituents</th><td>alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the polyamines. These are compounds containing more than one amine group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity. </td></tr><tr><th>Pharmacodynamics</th><td>Polidocanol has a concentration and volume dependent damaging effect on the blood vessel endothelium. </td></tr><tr><th>Mechanism of action</th><td>When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.</td></tr><tr><th>Absorption</th><td>When given intravenously, the maximum blood concentrations were reached in 15 mins.</td></tr><tr><th>Volume of distribution</th><td><p>When given intravenously, the volume of distribution was 35-82L.</p></td></tr><tr><th>Protein binding</th><td>Plasma protein binding was not measured.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism was not measured.</p></td></tr><tr><th>Route of elimination</th><td>Route of elimination was not indicated.</td></tr><tr><th>Half life</th><td>The half-life is approximately 1.5 h. </td></tr><tr><th>Clearance</th><td><p>Sytemic clearance was 0.2-0.4 L/min.</p></td></tr><tr><th>Toxicity</th><td>Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9925</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.953</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6567</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5355</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6835</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6914</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8478</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8073</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8293</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6911</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8073</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9035</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9389</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8847</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9155</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9568</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9665
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5325
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.8025
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8785 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8213
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5969
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection</td><td>Intravenous</td><td>0.5%</td></tr><tr><td>Injection</td><td>Intravenous</td><td>1%</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>180MG/18ML (10MG/ML) </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td>Searched, but no interactions found.</td></tr><tr><th>Food Interactions</th><td>Searched, but no interactions found.</td></tr></tbody></table>